Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-7386 in Prostate Cancer
NCT04421222Phase 1Terminated
- Sponsor
- ESSA Pharma
- Start
- Jun 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of masofaniten in castration-resistant prostate cancer (CRPC) and prostate cancer (PCa) (15 arms), sponsored by ESSA Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Proportion of patients with PSA decline >=50% and >=90% at 4 months and 1 more. Started Jun 2020; status: terminated.
02
Drugs
masofaniten
03
Conditions
castration-resistant prostate cancer (CRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04421222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421222.